Innate Pharma IPHA
NASDAQ IPHA
$1.67 +0.07 (+4.43%)
As of: Sep 30, 2026 · 12:27 PM EDT

Innate Pharma SA (IPHA) EBIT Margin (2020 - 2025)

Updated

Innate Pharma (IPHA) reported EBIT Margin of -402284.62% for the quarter ended Dec 31, 2025, up 83588.11 percentage points from -485872.73% a year earlier.

Analysis

Innate Pharma SA (IPHA) EBIT Margin (2020 - 2025) Analysis & Trends

For the year ended Dec 31, 2025, Innate Pharma posted EBIT Margin of -599.76%, down 343.43 percentage points from the prior year.

  • EBIT Margin has a five-year change of -601.30 percentage points (years ended Dec 2020 to Dec 2025).
  • By year, EBIT Margin came in at -256.32% in the year ended Dec 31, 2024 (-235.77 pp), -20.55% in the year ended Dec 31, 2023 (+79.02 pp), -99.57% in the year ended Dec 31, 2022 (+94.03 pp) and -193.60% in the year ended Dec 31, 2021 (-195.15 pp).
  • The figure for the quarter ended Dec 31, 2025 ranks as the highest quarterly EBIT Margin since the quarter ended Dec 31, 2023.
Peer Set

Peer Comparison

Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 -402,284.62%
Dec 31, 2024 -485,872.73%
Dec 31, 2023 -85,500.00%
Dec 31, 2022 -107.28%
Dec 31, 2020 -1,119.76%
API Access

Innate Pharma SA EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=IPHA&period=max&api_key=YOUR_API_KEY